Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 11 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| MAXCYTE, INC. | 10,000,000 | reported | 03 Oct 2022 | tx 2−3,971,334 |
| BIOLIFE SOLUTIONS INC | 6,707,165 | reported | 15 Aug 2025 | tx 2+1,600,000−500,000 |
| Tenaya Therapeutics, Inc. | 6,078,860 | reported | 17 Nov 2022 | tx 2+3,846,153 |
| GeneDx Holdings Corp. | 3,507,164 | reported | 20 May 2026 | tx 9+1,530,000 |
| 2seventy bio, Inc. | 2,000,000 | reported | 26 Mar 2024 | tx 1+40,000 |
| Absci Corp | 0 | reported | 26 Jul 2021 | tx 7+7,718,593−1,274,431 |
| STANDARD BIOTOOLS INC. | 0 | reported | 28 Feb 2025 | tx 7+6,624,174−1,745,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 18 May 2026 | PURCHASE | GeneDx Holdings Corp. | 175,000 | 42.55 USD | |
| 19 May 2026 | PURCHASE | GeneDx Holdings Corp. | 185,000 | 42.60 USD | |
| 20 May 2026 | PURCHASE | GeneDx Holdings Corp. | 140,000 | 43.81 USD | |
| 07 May 2026 | PURCHASE | GeneDx Holdings Corp. | 500,000 | — | derivfirst after silence |
| 08 May 2026 | PURCHASE | GeneDx Holdings Corp. | 300,000 | — | deriv |
| 11 May 2026 | PURCHASE | GeneDx Holdings Corp. | 50,000 | — | deriv |
| 15 Aug 2025 | SALE | BIOLIFE SOLUTIONS INC | 500,000 | 24.40 USD | |
| 28 Feb 2025 | OTHER | STANDARD BIOTOOLS INC. | 545,000 | 1.07 USD | |
| 28 Feb 2025 | OTHER | STANDARD BIOTOOLS INC. | 545,000 | 1.07 USD | |
| 28 Feb 2025 | PURCHASE | STANDARD BIOTOOLS INC. | 4,820,959 | 1.07 USD | |
| 28 Feb 2025 | GRANT_AWARD | STANDARD BIOTOOLS INC. | 58,215 | 1.07 USD | |
| 18 Jun 2024 | OTHER | STANDARD BIOTOOLS INC. | 655,000 | 2.05 USD | |
| 18 Jun 2024 | OTHER | STANDARD BIOTOOLS INC. | 1,200,000 | 2.05 USD | |
| 18 Jun 2024 | OTHER | STANDARD BIOTOOLS INC. | 545,000 | 2.05 USD | |
| 04 Jun 2024 | PURCHASE | GeneDx Holdings Corp. | 30,000 | 22.52 USD | |
| 03 Jun 2024 | PURCHASE | GeneDx Holdings Corp. | 100,000 | 20.82 USD | |
| 13 May 2024 | PURCHASE | GeneDx Holdings Corp. | 50,000 | 23.31 USD | |
| 26 Mar 2024 | PURCHASE | 2seventy bio, Inc. | 40,000 | 5.10 USD | first after silence |
| 17 Nov 2022 | PURCHASE | Tenaya Therapeutics, Inc. | 2,492,042 | 2.60 USD | first after silence |
| 17 Nov 2022 | PURCHASE | Tenaya Therapeutics, Inc. | 1,354,111 | 2.60 USD | deriv |
| 03 Oct 2022 | SALE | MAXCYTE, INC. | 735,786 | 6.15 USD | |
| 01 Jul 2022 | SALE | MAXCYTE, INC. | 3,235,548 | 4.30 USD | |
| 26 Jul 2021 | CONVERSION | Absci Corp | 973,260 | 0.00 USD | |
| 26 Jul 2021 | PURCHASE | Absci Corp | 1,562,500 | 16.00 USD | |
| 26 Jul 2021 | CONVERSION | Absci Corp | 973,260 | 0.00 USD |
3 purchases reported after at least 12 months of silence — most recent on 07 May 2026.